financetom
Business
financetom
/
Business
/
Welltower Q1 Normalized FFO, Revenue Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Welltower Q1 Normalized FFO, Revenue Increase
Apr 29, 2024 2:11 PM

04:47 PM EDT, 04/29/2024 (MT Newswires) -- Welltower ( WELL ) reported late Monday Q1 normalized funds from operations of $1.01 per diluted share, up from $0.85 a year earlier.

Analysts polled by Capital IQ expected FFO of $0.95.

Revenue for the quarter ended March 31 was $1.86 billion, up from $1.56 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.86 billion.

The company said it increased the guidance range for full-year 2024 normalized FFO to between $4.02 and $4.15 per diluted share from the previous guidance between $3.94 and $4.10.

Analysts polled by Capital IQ expect FFO of $4.06.

Price: 94.44, Change: -1.34, Percent Change: -1.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NuVista Energy Reduces Production Guidance After Unscheduled Third-Party Downtime
NuVista Energy Reduces Production Guidance After Unscheduled Third-Party Downtime
Dec 18, 2024
08:32 AM EST, 12/18/2024 (MT Newswires) -- NuVista Energy ( NUVSF ) on Wednesday reduced its production guidance for the fourth quarter due to an unscheduled downtime at a third-party gas plant. The company said it temporarily curtailed production in the greater Wapiti area following the disruption impacting its production volumes in December. As a result, NuVista lowered its production...
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
Dec 18, 2024
08:31 AM EST, 12/18/2024 (MT Newswires) -- Corvus Pharmaceuticals ( CRVS ) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile. The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity...
LiveOne Says Collaboration With Tesla Surpassed 350,000 Paid Subscribers
LiveOne Says Collaboration With Tesla Surpassed 350,000 Paid Subscribers
Dec 18, 2024
08:30 AM EST, 12/18/2024 (MT Newswires) -- LiveOne ( LVO ) said Wednesday its multiyear collaboration with Tesla (TSLA) reached 350,000 paid subscribers as of Dec. 15. ...
HBT Financial Board Approves up to $15 Million Share Buyback Plan
HBT Financial Board Approves up to $15 Million Share Buyback Plan
Dec 18, 2024
08:30 AM EST, 12/18/2024 (MT Newswires) -- HBT Financial ( HBT ) said Wednesday its board approved an up to $15 million share buyback plan, to take effect after its current plan expires Jan. 1. The new buyback plan will be in effect until Jan. 1, 2026, the company said. Shares of the company were down 1.6% in recent Wednesday...
Copyright 2023-2026 - www.financetom.com All Rights Reserved